文献速递小儿泌尿与泌尿修复

葡聚糖微球内镜下注射治疗膀胱外翻-尿道上裂复合体尿失禁

Dextranomer Endoscopic Injections for the Treatment of Urinary Incontinence in Bladder Exstrophy-epispadias Complex.
PubMed 文献 · J Urol · 2022-11-30

该研究纳入1997年10月至2021年1月在本院接受膀胱颈葡聚糖微球/透明质酸共聚物(Deflux)注射的58例膀胱外翻-尿道上裂复合体尿失禁患儿,共105次注射,中位年龄8.5岁。结果显示5年无失败生存率在男性尿道上裂为70%(标准误9.1),女性尿道上裂及膀胱外翻患者为45%(9.0),两组比较P=0.04。作者认为该注射治疗可使超过半数患者获得满意且持久的控尿。

要点

  • 58例患儿共接受105次膀胱颈Deflux注射,并发症发生率为9%。
  • 男性尿道上裂5年无失败生存率为70%(标准误9.1),女性及膀胱外翻患者为45%(标准误9.0),P=0.04。
  • 女性及膀胱外翻患者中,既往行膀胱颈重建者5年无失败生存率为58%(标准误11),未行者未报告。

核心结论

  • Deflux注射可使超过半数膀胱外翻-尿道上裂复合体患者获得满意且持久的控尿。
  • 男性尿道上裂患者无论膀胱颈重建时机如何注射均成功,而膀胱外翻及女性尿道上裂患者在既往膀胱颈重建后效果更好。

研究设计与样本

  • 回顾性纳入1997年10月至2021年1月在本院接受膀胱颈Deflux注射的>4岁膀胱外翻-尿道上裂复合体尿失禁患儿58例,共105次注射。

主要发现

  • 58例中男性尿道上裂27例、女性尿道上裂9例、膀胱外翻22例,中位年龄8.5岁(四分位距5.8-12)。
  • 既往行膀胱颈重建者38例(66%),接受多次注射者33例(57%)。
  • 并发症发生率为9%。
  • 5年无失败生存率男性尿道上裂为70%(标准误9.1),女性尿道上裂及膀胱外翻患者为45%(标准误9.0),P=0.04。
  • 女性及膀胱外翻患者中,既往膀胱颈重建者5年无失败生存率为58%(标准误11);男性尿道上裂中为75%(标准误11)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Since bladder neck dextranomer/hyaluronic acid copolymer (Deflux) injections can improve urinary incontinence of various etiologies, we hypothesized that incontinent children with bladder exstrophy-epispadias complex would benefit from dextranomer/hyaluronic acid copolymer. We aimed to analyze dextranomer/hyaluronic acid copolymer efficacy and predictors of treatment success in bladder exstrophy-epispadias complex. MATERIALS AND METHODS: Incontinent bladder exstrophy-epispadias complex children aged >4 years undergoing dextranomer/hyaluronic acid copolymer injections in our hospital between October 1997 and January 2021 were included. Medical history, continence, and bladder capacity before injections were recorded. Postoperatively, patients were categorized as "dry," "significantly improved," or "failure." Postoperative complications, bladder emptying mode, and bladder capacity were reported. Failure-free survival was estimated by Kaplan-Meier models. RESULTS: Altogether, 58 patients (27 male epispadias, 9 female epispadias, 22 bladder exstrophy) underwent 105 injections at median age of 8.5 (interquartile range 5.8-12) years. Previous bladder neck reconstruction had been performed in 38 (66%) and 33 (57%) received multiple injections. Complications occurred in 9%. Five-year failure-free survival was 70% (standard error 9.1) in males epispadias compared to 45% (9.0) in females and exstrophy patients (P = .04). Previous bladder neck reconstruction associated with improved 5-year failure-free survival in females and exstrophy patients (58%, SE 11) but not in male epispadias (75%, SE 11). CONCLUSIONS: Dextranomer/hyaluronic acid copolymer injections provided satisfactory and lasting continence in over half of bladder exstrophy-epispadias complex patients. While injections were successful in male epispadias regardless of bladder neck reconstruction timing, results were better in bladder exstrophy and female epispadias after previous bladder neck reconstruction.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Fiorenza V, Hukkinen M, Alova I, et al. Dextranomer Endoscopic Injections for the Treatment of Urinary Incontinence in Bladder Exstrophy-epispadias Complex. J Urol. 2022. PMID: 36449491. doi:10.1097/JU.0000000000003086

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。